QS Investors’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

QS Investors’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-64,800	Closed	-$2.44M	–	1275
2021 Q1	$2.44M	Sell	64,800 -1,900	-3%	-$47.4K	0.03%	335
2020 Q4	$1.14M	Buy	66,700 +19,900	+43%	+$249K	0.01%	460
2020 Q3	$220K	Buy	46,800 +44,300	+1,772%	+$225K	﹤0.01%	1052
2020 Q2	$16K	Hold	2,500	–	–	﹤0.01%	1511
2020 Q1	$6K	Buy	2,500 +1,500	+150%	+$6.37K	﹤0.01%	1599
2019 Q4	$5K	Hold	1,000	–	–	﹤0.01%	1598
2019 Q3	$4K	Buy	+1,000	New	+$5.49K	﹤0.01%	1618
2017 Q1	–	Sell	-17,400	Closed	-$872K	–	2042
2016 Q4	$872K	Sell	17,400 -37,400	-68%	-$1.96M	0.01%	785
2016 Q3	$2.88M	Buy	54,800 +16,000	+41%	+$764K	0.02%	554
2016 Q2	$1.6M	Buy	+38,800	New	+$1.69M	0.01%	684

QS Investors's FPRX Position: Q2 2021 in Review

QS Investors sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 64,800 shares — an estimated $2.44M sold.

QS Investors first reported a position in FPRX in Q2 2016 and held it in 10 quarters. The position peaked at $2.88M in Q3 2016. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

QS Investors reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
QS Investors sold 64,800 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $2.44M.
QS Investors first reported a position in Five Prime Therapeutics, Inc. in Q2 2016 and held it in 10 quarters.
QS Investors's Five Prime Therapeutics, Inc. position peaked at $2.88M in Q3 2016.
0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.